QPS, a CRO that offers drug discovery and development services, has purchased a majority stake in a Phase 1 Indian CRO, Bioserve Clinical Research; that will be known as QPS-Bioserve India.
Subscribe to our email newsletter
Bioserve’s services include Phase I & Bioavailability/Bioequivalence studies, PK in Patient Populations, Bioanalytical Services, Statistical & IVIVC Analysis, Pharmacoscintigraphic Imaging, Clinical Trial Management and Regulatory Affairs.
QPS president and CEO Ben Chien said the new partnership further expands QPS’ global range of linearly integrated services.
"With access to Bioserve’s additional resources, our customers will have the heightened benefits of a third more phase I beds, bringing our total to 400; greater bioanalytical capacity; and access to another facility, located in India, with a reputation for outstanding performance and a record of timely approvals," Chien said.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.